Our results indicate variation in practice among providers at ECU ID Clinic regarding the screening, the need for a follow-up, and the type of follow-up provided. Additionally, research shows that anal cancer is one of the non-defining AIDS cancers whose incidence increases as the patient ages. However, based on the data, anal cancer screening decreases as the patient ages at the ECU ID clinic. Therefore, a standardized clinic protocol is needed, which may help improve the screening and follow-up rates. Also, a higher percentage of patients with an ASCUS result do not receive follow-up when compared with patients with an LGSIL and HGSIL result. Future research to determine the significance of follow-up for patients with an ASCUS result should be explored.
Immunogenicity of Takeda's Bivalent Virus-Like Particle (VLP) Norovirus Vaccine (NoV) Candidate in Children From 6 Months up to 4 Years of Age
Background. With the introduction of routine childhood rotavirus vaccination, norovirus is now becoming the major cause of medically-attended gastroenteritis in children. Takeda is developing a norovirus vaccine (NoV) that contains genotypes GI.1 and GII.4 consensus (GII.4c) sequence VLPs. We report the immunogenicity data of NoV administered to children from 6 months up to 4 years of age.
Methods. Two age cohorts (1 to < 4 years, and 6 to < 12 months, n = 120 per cohort) were enrolled in this ongoing double-blind, randomized, phase 2 dose-finding study conducted in Colombia and Panama. Children received one or two intramuscular doses of NoV formulations containing 15/15, 15/50, 50/50 or 50/150 μg of GI.1/ GII.4c VLPs adjuvanted with 0.5 mg Al(OH) 3 . Vaccinations were on Days 1 and 29, with saline placebo as dose two to maintain blinding in one dose groups. Antibody responses to each VLP were measured on days 1, 29 and 57 as functional histo-blood group binding antigen blocking antibodies (HBGA), expressed as seroresponse rates (SRR), the proportions displaying ≥ 4-fold increases over baseline, and geometric mean titres (GMT).
Results. Each formulation induced dosage-dependent HBGA responses after a single dose, with a further increase after a second dose. In 1-to <4 year-olds HBGA SRR against GI.1 and GII.4c after one dose were 55-62% and 67-82%, respectively. SRR increased to 93-100% and 83-100% after a second dose. In 6 to < 12 month-olds responses were lower after the first dose: SRRs were 10-61% and 17-65% for GI.1 and GII.4c, respectively, increasing to 83-100% and 80-92% after a second dose. GMTs reflected this pattern of responses with higher GMTs for GI.1 and GII.4c achieved with the 50/150 μg formulation than the other dosages after both vaccinations in both age cohorts.
Conclusion. In 6-12 month-old infants and children up to 4 years of age, robust immune responses to the bivalent norovirus VLP vaccine candidates were observed; the highest HBGA responses in both age cohorts were observed after two doses of the 50/150 μg formulation. Further clinical evaluation of these formulations is underway in infants < 6 months of age.
Clinical Results. From 1075 suspected cases, 350(32.6%) were Bp confirmed cases; median age 3 months (IQ = 2-7 months), 38% <3 months, 68% <6 months, 83% <12 months; 55% females; 18% had comorbidities; prematurity 10%, malnourishment 1%, and immunosuppression 1%; 81% required hospitalization, median length of stay was 6 days (IQ = 4-10 days), 17% in UCI. Confirmed cases showed a seasonal pattern predominantly from September through February (spring-summer). In comparison with PreV, PostVcases were older (3 vs. 9 months; P < 0.001), required less hospitalization (87% vs. 68%; P < 0.001), HR (22.3 vs. 10.9; P < 0.001) and LR (6.8% vs. 0%; P = 0.03) decreased and had a higher proportion of complete primary vaccination schedule (44% vs. 11%, P < 0.001). No difference found in gender (females 62% vs. 54%; P = 0.23), length of stay days (P = 0.51) or intensive care requirement (18% vs. 17%; P = 0.91). All fatal cases occurred in PreV.
Conclusion. After maternal immunization strategy Bp confirmed cases were older, required less hospitalization and had a higher proportion of complete primary vaccination schedule. Hospitalization and lethality rates showed a significant decrease. There were no fatal cases in our center after this intervention.
Disclosures. Background. The Advisory Committee on Immunization Practices (ACIP) recommends maternal immunization (MI) with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during every pregnancy, preferably between 27-36 weeks of gestation, as well as influenza vaccination for all women who are pregnant or who might be pregnant in the influenza season.
Methods. This retrospective cohort analysis characterizes the rate of Tdap and influenza vaccination among large national samples of pregnant women in the United States using administrative claims data. The MarketScan® Commercial Claims and Encounters ("Commercial") and the Multi-State Medicaid Databases ("Medicaid") were used to identify pregnancies between January 1, 2010 and April 30, 2017. Diagnosis and procedure codes that describe gestational age at pregnancy end were used to estimate the date of last menstrual period (LMP) or the index date (Figure 1) . Eligible pregnancies had ≥6 months of continuous enrollment prior to index date
